Development of an Active Chimeric IL13Rα2 ADC for Diffuse Intrinsic Pontine Glioma.

44 But a strong trend in the pharmaceutical field related to the anti-HER2 ADC trastuzumab deruxtecan drives us to pursue deruxtecan.

also in 5,725 other papers

For the cell line SF-8628 with high IL13Rα2 expression, the ADC and payload treatment resulted in a similar trend in decreased tumor viability but did not reach statistical significance due to variability in the vehicle control and chimeric mAb cohorts ( Figure 5d ).

also in 111,027 other papers